ATyr Pharma, Inc. (ATYR) Announces Top Line Results For The Phase III EFZO-FIT Study Of Efzofitimod In Pulmonary Sarcoidosis (Transcript)
aTyr Pharma, Inc. (NASDAQ:ATYR ) Announces Top Line Results for the Phase III EFZO-FIT Study of Efzofitimod in Pulmonary Sarcoidosis September 15 2025 11:00 AM EDT Company Participants Ashlee Dunston - Director of Investor Relations & Corporate Communications Sanjay Shukla - President, CEO & Director Robert Bachman Jill Broadfoot - Chief Financial Officer Conference Call Participants Derek Archila - Wells Fargo Securities, LLC, Research Division Yasmeen Rahimi - Piper Sandler & Co., Research Division Faisal Khurshid - Leerink Partners LLC, Research Division Joseph Pantginis - H.C. Wainwright & Co, LLC, Research Division Prakhar Agrawal - Cantor Fitzgerald & Co., Research Division Jiale Song - Jefferies LLC, Research Division Brian Abrahams - RBC Capital Markets, Research Division Yale Jen - Laidlaw & Company (UK) Ltd.
aTyr Pharma: Good Safety Data In Pulmonary Sarcoidosis, Institutions Are Accumulating
aTyr Pharma's pivotal data readouts in 2025 for SSc-ILD (Phase 2) and pulmonary sarcoidosis (Phase 3) could significantly impact its market potential and approval prospects. Efzofitimod shows promise in reducing fibrosis without immunosuppression, with recent safety data and a peer-reviewed publication bolstering confidence in its efficacy. Institutional ownership has surged to nearly 80%, indicating strong institutional confidence despite the inherent risks associated with earlier trial failures.
aTyr Pharma, Inc. (ATYR) Q4 2024 Earnings Call Transcript
aTyr Pharma, Inc. (NASDAQ:ATYR ) Q4 2024 Earnings Conference Call March 13, 2025 5:00 PM ET Company Participants Ashlee Dunston - Senior Director of Investor Relations and Public Affairs Sanjay Shukla - President and Chief Executive Officer Leslie Nangle - Vice President of Research Jill Broadfoot - Chief Financial Officer Conference Call Participants Derek Archila - Wells Fargo & Company Yasmeen Rahimi - Piper Sandler Companies Faisal Khurshid - Leerink Partners LLC Prakhar Agrawal - Cantor Fitzgerald, L.P. Gregory Renza - RBC Capital Markets Joe Pantginis - H.C.
aTyr Pharma: The Bull Has Finally Come Out
aTyr Pharma has a pivotal year ahead with key readouts for Efzofitimod in pulmonary sarcoidosis and SSC-ILD, potentially opening a huge market. Efzofitimod aims to modulate inflammation without immune suppression, setting it apart from traditional treatments, with promising post-hoc results in higher doses. aTyr is well-funded with $81 million in cash, sufficient for upcoming trial readouts, and has seen significant stock performance and insider buying.
aTyr Pharma: Two 2025 Data Readouts Could Provide Inflection Point
Topline data from phase 3 EFZO-FIT study, using efzofitimod for the treatment of patients with pulmonary sarcoidosis, expected Q3 of 2025. The 7 major pulmonary sarcoidosis markets are expected to reach a value of $53.3 billion by 2034. Topline data from the phase 2 EFZO-CONNECT study, using efzofitimod for the treatment of patients with scleroderma-related ILD, expected Q2 of 2025.
